AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01414387 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid reversal of flow
Description: On the flow reversal arm two type of devices will be used. The first is the Gore flow reversal system, manufactured by LW Gore and the second device is the IVANTEC MoMa Ultra Embolic protection device, manufatured by IVANTEC.
Study NCT03813940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine,135μg/0.5ml
Description: HPV vaccine (135μg/0.5ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
Study NCT03813940 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV Vaccine,270μg/1.0ml
Description: HPV vaccine (270μg/1.0ml) administered intramuscularly according to a 0, 1, 6 month vaccination schedule
Study NCT04588350 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-SEP autotransfusion system
Description: Intraoperative recovery and washing of the processed blood by i-SEP autotransfusion system in surgeries where a bleeding is expected
Study NCT03734627 — intervention group
Intervention type: DRUG
Intervention: Octreotide Acetate
Description: 50mcg octreotide acetate by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
Study NCT02056184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Study NCT02056184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Study NCT01797887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and Lifestyle Counseling
Description: Diet and Lifestyle Counseling
Study NCT01797887 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet and Lifestyle Counseling
Description: Diet and Lifestyle Counseling
Study NCT02069041 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV.
Study NCT02069041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX4
Description: Administered IV.
Study NCT03476889 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Infant formula
Description: Infants are randomized to one of two infant formulas from \<14 days of age to 17 weeks of age.
Study NCT03476889 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant formula
Description: Infants are randomized to one of two infant formulas from \<14 days of age to 17 weeks of age.
Study NCT04122313 — intervention group
Intervention type: OTHER
Intervention: Evaluation of Dupuytren's Disease Treatment
Description: There are no study interventions. The study interaction will be asking the patients to complete an additional outcome questionnaire and allow a medical record review.
Study NCT01707966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orteronel
Study NCT01707966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT00230659 — intervention group
Intervention type: OTHER
Intervention: Blood sample to be taken.
Description: Blood sample to be taken.
Study NCT04002115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Clofarabine to be administered pre-stem cell transplant infusion (Day 0) once a day for 5 days total.
Study NCT04002115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be administered once a day for 4 days as part of the transplant conditioning regimen.
Study NCT04002115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Busulfan will be administered once a day for 2 days as part of the transplant conditioning regimen.
Study NCT04002115 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation (TBI)
Description: TBI will be administered at a dose of 200cGys on Day -1 prior to transplant
Study NCT04002115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be given once a day for 2 days after the transplant infusion.
Study NCT04002115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor
Description: G-CSF will be administered to subjects starting on Day +5 and will continue as clinically indicated
Study NCT04002115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Tacrolimus will be administered to subjects starting on Day +5 and will continue as clinically indicated
Study NCT04002115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellcept
Description: Mycophenolate Mofetil will be administered to subjects starting on Day +5 and will continue as clinically indicated
Study NCT00463047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone
Description: Patients will be randomly assigned in a 1:1 ratio either to titrate immediate-release oxycodone first and to titrate FBT second, or to titrate FBT first and immediate-release oxycodone second, followed by 2 double-blind crossover treatment periods (in randomized order). For the double-blind treatment period of the study involving FBT administration, a patient is randomly assigned to receive FBT at the 200, 400, 600, or 800 mcg strength found to be successful during open-label titration. For the double-blind treatment period of the study to which a patient is randomly assigned to receive immediate-release oxycodone, the patient will receive immediate-release oxycodone at the strength (15, 30, 45, or 60 mg) found to be successful during open-label titration.
Study NCT00463047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone
Description: Patients will be randomly assigned in a 1:1 ratio either to titrate immediate-release oxycodone first and to titrate FBT second, or to titrate FBT first and immediate-release oxycodone second, followed by 2 double-blind crossover treatment periods (in randomized order). For the double-blind treatment period of the study involving FBT administration, a patient is randomly assigned to receive FBT at the 200, 400, 600, or 800 mcg strength found to be successful during open-label titration. For the double-blind treatment period of the study to which a patient is randomly assigned to receive immediate-release oxycodone, the patient will receive immediate-release oxycodone at the strength (15, 30, 45, or 60 mg) found to be successful during open-label titration.
Study NCT00140244 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-metHuLeptin
Study NCT00140244 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01709682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anti-Arrhythmia Agents (propafenone, flecainide, and/or sotalol, or amiodarone)
Description: propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure
Study NCT01709682 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: re-ablation procedure
Description: Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.
Study NCT01709682 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ILR implantation
Description: The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.~Patients were provided with the Patient Assistant, a tool that allows each patient to store the ECG through the implanted device during symptoms; data were collected in order to analyze heart rhythm during symptomatic events.
Study NCT03616873 — intervention group
Intervention type: OTHER
Intervention: Early Mobilization
Description: The EM program consists of a progression of functional activities from level of function (LOF) 0 (lowest mobility) to 5 (highest mobility). Each LOF has 3 primary activities designed to promote the patient to the next level. The nurse will begin with mobility activities based on the LOF that matches the patient's current status. The nurse and clinical partner will attempt and/or complete each LOF activity once per shift.
Study NCT03418233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CardioCell
Description: Patients randomized to the active treatment group will receive transcoronary or trans-bypass graft administration of 30 000 000 cells (suspended in 20 ml of 0.9% NaCl and 5% albumin).~Injection will be performed using a dedicated cell delivery catheter. The cell delivery catheter is a typical coronary balloon catheter that is CE marked (1.2x10 mm balloon, RX system) modified to include cell delivery perforations in the balloon section of the catheter. The cell delivery catheter has been demonstrated not to affect cell viability or other cell properties.
Study NCT03418233 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Patients randomized to the placebo group will receive Placebos consist 0.9% NaCl and 5% albumin injections (in the same volumes as CardioCell) via the coronary arter(ies)/bypass grafts. The CardioCell and placebo are distributed encoded, in an indistinguishable form.
Study NCT02262520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Study NCT02262520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Study NCT00356603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan Succinate
Description: Sumatriptan Succinate
Study NCT02458248 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sodium Reduction
Description: In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of \<100mmol/day (\<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions.
Study NCT00162110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetuximab
Description: mg, IV, 225 mg/m2, weekly, 4-52 weeks depending on response.
Study NCT05822323 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BTX-A
Description: Vials of 100 U Allergan Botox® (Allergan, Inc., Irvine, California) were diluted with 2 ml of physiological saline and made ready for use. The midline was determined at the mentum region. 5 U of BTX-A was injected into the mental muscle approximately 1 cm away from the chin tip and the midline
Study NCT05822323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: free gingival graft
Description: The mandibular first incisor was treated with FGG operation due to Miller class III gingival recession and insufficient amount of keratinized gingiva.
Study NCT05822323 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: free gingival graft
Description: The mandibular first incisor was treated with FGG operation due to Miller class III gingival recession and insufficient amount of keratinized gingiva.
Study NCT02143973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nalbuphine HCl ER
Description: nalbuphine HCl ER
Study NCT01464424 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Travoprost 0.004% ophthalmic solution
Study NCT01464424 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bimatoprost 0.01% ophthalmic solution
Study NCT00937027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminopterin
Description: oral tablets, 1.0 mg dose, once weekly, two weeks
Study NCT01295827 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes on Day 1 of each cycle, administered according to dose selection or randomization.
Study NCT03734627 — intervention group
Intervention type: DRUG
Intervention: Saline Solution
Description: Equivalent volume of 0.9% saline by subcutaneous injection 10 minutes prior to a 400kcal mixed meal challenge
Study NCT06575231 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: in-vitro
Description: responding smartphone. It is intended for quantitative measurement of HbA1c in capillary whole blood and use in the home by people with diabetes mellitus as an aid to monitor the effectiveness of diabetes control.
Study NCT04614025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PLX-PAD
Description: PLX-PAD - allogeneic ex-vivo expanded placental mesenchymal-like adherent stromal cells
Study NCT01594736 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORSIRO
Description: due randomization ORSIRO will be implanted
Study NCT01594736 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE PRIME DES
Description: due randomization XIENCE PRIME DES will be implanted
Study NCT01234870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadolinium
Study NCT01234870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Study NCT02449798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuCath 2.25 BC Intravascular Catheter
Description: Long peripheral IV catheter designed for difficult IV access patients requiring deeper vessel access, often used with ultrasound guidance.
Study NCT03809780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: -high dose: \[lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly\] -Low dose: \[lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly\]
Study NCT03809780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: -high dose: \[lenalidomide 25mg day 1-21 plus dexamethasone 20mg weekly\] -Low dose: \[lenalidomide 15mg day 1-21 plus dexamethasone 10mg weekly\]
Study NCT04679532 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gx sweat patch
Description: Adhesive-backed flexible epidermal wearable regional sweat patch to collect and analyze sweat via microfluidics and colorimetric assay
Study NCT04679532 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Reference sweat patch
Description: Adhesive Tegaderm with absorbent pad regional sweat patch to collect sweat, followed by standard benchtop gravimetry and ion chromatography methods to analyze sweat
Study NCT02017431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allergen
Description: Subject specific allergen is inhaled on day 1 of the triad
Study NCT02017431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Allergen
Description: Subject specific allergen is inhaled on day 1 of the triad
Study NCT02017431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: Saline is inhaled on day 1 of the triad
Study NCT02017431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Particle depleted diesel exhaust
Description: High-efficiency particulate filtration of diesel exhaust
Study NCT03474185 — intervention group
Intervention type: BEHAVIORAL
Intervention: Taking Charge of your Heart Health patient education classes
Description: Taking Charge of your Heart Health patient education classes held at TotalCardiology cardiac rehabilitation in Calgary, Canada. Consists of four, 2.5-hour long group-based classes focused on focused on physiology, risk factors, medications, nutrition, exercise, and stress management
Study NCT02309762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB825
Description: FB825 will be supplied at a concentration of 20 mg/mL for a single dose IV injection
Study NCT02309762 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution containing no active ingredients
Study NCT02271152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FAST mapping and ablation
Study NCT02271152 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PVI
Study NCT02271152 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PVI
Study NCT01888055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Study NCT01888055 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham stimulation
Study NCT03656653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mental Imagery for Craving Reduction
Description: a behavioural mental imagery intervention where participants are asked to generate specific mental images to reduce cue-induced craving for cocaine use disorder
Study NCT01131364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F16IL2 in combination with doxorubicin
Description: Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 up to 25 MioIU) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 30-minute i.v. infusion of doxorubicin (Dose escalation: from 20 up to 25 mg/m2) on Days 1, 8, 15 29, 36 and 43.~Patients with objective tumor responses or stable disease will receive repeated cycles of treatment starting on Day 56. Patients will receive additional cycles of combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent.
Study NCT01541332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide administered to 3 cohorts of subjects at escalating doses of 2 (cohort 1), 3 (cohort 2) and 4 mg/dose (cohort 3) per orem (PO). Doses are to be administered once-a-day, for the first 21 days, as part of a 28-day treatment cycle, followed by a 7-day rest period.
Study NCT01541332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Description: Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.~PLD will be given at a dose of 5.0 mg/m2 as a 60 minute IV infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle.
Study NCT01541332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.
Study NCT01872117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shortwave therapy
Description: Will be conducted in four stages, on different days: i) lower limb in extension and application of 180° for 20 min, ii) Lower limb knee flexion of 90° and application for 20 min; iii) lower limb extension in 180° without application iv) lower limb knee flexion of 90° without application.
Study NCT01872117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Microwave therapy
Description: Will be held in two stages, on different days: i) lower limb in extension with angle of 180° and application for 20 min, ii) lower limb in extension of 180° without application.
Study NCT02519998 — intervention group
Intervention type: OTHER
Intervention: Concussion
Description: Study groups are differentiated based on presence of concussion. No intervention is being made in either population (observational study)
Study NCT02260336 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Panax Notoginseng Powder 1g
Study NCT02260336 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Panax Notoginseng Powder 5g
Study NCT02260336 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Panax Notoginseng Powder 10g
Study NCT02260336 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Panax Notoginseng Powder 15g
Study NCT02260336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib Capsule 400 mg daily
Study NCT02184338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 1017 BS powder
Study NCT02184338 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: PEG 400
Study NCT03658161 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Communicating About Sexual Concerns and Dysfunction Effectively
Description: The coaching intervention will include two parts: 1) initial coaching session, and 2) follow-up appointment to check in on use of the intervention strategies.
Study NCT03734627 — intervention group
Intervention type: DRUG
Intervention: Paracetamol
Description: Paracetamol 1g by mouth consumed with a 400kcal mixed meal challenge
Study NCT03734627 — intervention group
Intervention type: DRUG
Intervention: Sulfasalazine
Description: 1g sulfasalazine by mouth consumed with a 400kcal mixed meal challenge
Study NCT03734627 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Duodenal biopsy
Description: Biopsy from the second part of the duodenum taken at routine endoscopic surveillance, undertaken for another clinical indication.
Study NCT02739438 — intervention group
Intervention type: OTHER
Intervention: Electronic cigarette use
Description: Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months.
Study NCT02739438 — intervention group
Intervention type: OTHER
Intervention: Cigarette use
Description: Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.